Lifevantage Corp
Close on Oct 19, 2026
- Market cap
- $74.97M
- P/E (TTM)
- 15.0
- Dividend yield
- 3.09%
About Lifevantage
Pharmaceutical Preparations, SIC 2834
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, weight management and gut health products, nootropics, and personal care items. Its principal offerings include Protandim dietary supplements, TrueScience skin and hair care products, the MindBody GLP-1 and Rise AM & Reset PM systems, AXIO drink mixes, and Petandim companion pet supplements. The company distributes its products through a network marketing direct sales model, utilizing independent consultants as well as direct consumer transactions and subscription programs.
The company operates internationally, commercializing products across North America, Europe, Asia, and Australasia. Its geographic markets include the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, Iceland, and Portugal. LifeVantage also sells products into several other countries exclusively for personal consumption. The company maintains its corporate headquarters in Lehi, Utah.
Summary of the business section of Lifevantage's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Lifevantage Corp
- Founded
- 1988
- Headquarters
- Lehi, UT
- Address
- 3300 Triumph Blvd, Suite 700 84043
- Phone
- (801) 432-9000
- Website
- www.lifevantage.com
- Employees
- 223, Jun 30, 2026
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Salt Lake City, Utah
Stock & identifiers
- Ticker
- LFVN
- Exchange
- Nasdaq
- Shares outstanding
- 13M, Aug 26, 2026
- Public float
- $63.70M, Dec 31, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-7 reverse, Oct 19, 2015; 1-for-7 reverse, Oct 19, 2015; 1-for-68 reverse, Oct 5, 2004
- SEC CIK
- 849146
- CUSIP
- 53222K205
- ISIN
- US53222K2050
- LEI
- 5493001Z5YYT109QZ980
- EIN
- 90-0224471
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Terrence Moorehead | President and CEO, Director | 308,642 |
| Steven R. Fife | President and CEO, Director | 735,471 |
| Carl Aure | Chief Financial Officer | 156,495 |
| Kristen Cunningham | Chief Sales Officer | 120,162 |
| Alissa Neufeld | General Counsel | 112,744 |
| Todd Thompson | Chief Information Officer | 50,729 |
| Julie Boyster | Chief Marketing Officer | 150,088 |
| Darwin Lewis | Director | 138,244 |
| Michael A. Beindorff | Director | 74,821 |
| Judd Dayton | Director | 829,684 |
| Cynthia Latham | Director | 64,879 |
| Rajendran Anbalagan | Director | 23,999 |
| Raymond B. Greer | Director | 112,819 |
| Garry Paul Mauro | Director | 257,821 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Michael Beindorff | $233.00K | $178.54K | $786.05K | $49 | – |
| FY2026 Steven RFife | $2.19M | -$218.72K | $786.05K | $49 | – |
| FY2025 Michael Beindorff | $0 | $0 | $1.01M | $206 | – |
| FY2025 Steven R. Fife and Michael Beindorff | $2.82M | $7.47M | $1.01M | $206 | – |
| FY2025 Steven RFife | $2.82M | $7.47M | $1.01M | $206 | – |
| FY2024 Michael Beindorff | $0 | $0 | $703.97K | $160 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of June 30, 2026, we had 223 employees, 209 of which were full-time employees.”
Corporate history
Events identified from SEC filings